McKesson Corporation
As of Fiscal Year 2025 (ended March 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total revenue (FY2025) | $359.05 billion, up 16% year-over-year |
| GAAP net income attributable to McKesson (FY2025) | $3.295 billion, up 10% year-over-year |
| GAAP diluted EPS (FY2025) | $25.72 |
| Adjusted EPS (FY2025) | $33.05, up 20% year-over-year |
| Gross profit (FY2025) | $13.3 billion, up 4% year-over-year |
| Adjusted operating profit (FY2025) | $5.62 billion |
| Operating cash flow / Free cash flow (FY2025) | $6.1 billion / $5.2 billion |
| Employees (as of March 31, 2025) | approximately 45,000 worldwide (36,000 in the U.S., 5,000 in Canada, 4,000 elsewhere) |
| U.S. pharmaceutical distribution market context | McKesson is one of the 'Big Three' U.S. drug distributors (with Cencora and Cardinal Health) that together account for over 90% of U.S. drug distribution by revenue (Morningstar, May 2025 estimate) |
| Capital deployment (FY2025) | $3.1 billion share repurchases, $345 million dividends, $859 million capital expenditures |
Sources: McKesson's fiscal year ends March 31. Revenue and segment figures are company-disclosed GAAP results from McKesson's Q4/full-year FY2025 earnings release and Form 10-K. Segment operating profit figures are the company's non-GAAP 'Adjusted Operating Profit' measure (as reported by segment), used because GAAP segment operating income is not broken out separately in the earnings release. In February 2025 McKesson announced its intent to separate the Medical-Surgical Solutions segment into an independent company; that segment's FY2025 results are shown as reported prior to any separation. The '90%+ of U.S. drug distribution' figure is a third-party estimate (Morningstar, May 2025) describing the combined share of McKesson, Cencora, and Cardinal Health collectively -- individual company market share was not available from a credibly-sourced, dated third party, so it is presented as industry context in the KPI table rather than as a market-share pie.